Recursion Pharmaceuticals (RXRX) Exchange Rate Effect (2022 - 2026)
Recursion Pharmaceuticals (RXRX) posted Exchange Rate Effect of -$3.8 million for Q1 2026, down 283.61% on a QoQ basis from $2.1 million in Q4 2025, and down 179.29% year-over-year from $4.8 million in Q1 2025.
Recursion Pharmaceuticals (RXRX) Exchange Rate Effect (2022 - 2026) Analysis & Trends
Recursion Pharmaceuticals' Exchange Rate Effect history runs 5 years deep, the most recent figure standing at -$3.8 million for Q1 2026.
- Quarterly Exchange Rate Effect fell 179.29% year-over-year to -$3.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.4 million (up 469.81% YoY) and the FY2025 annual result came in at $18.0 million, up 629.77% from the prior year.
- Exchange Rate Effect was -$3.8 million for Q1 2026 at Recursion Pharmaceuticals, down from $2.1 million in the prior quarter.
- Across five years, Exchange Rate Effect topped out at $9.3 million in Q2 2025 and bottomed at -$3.8 million in Q1 2026.
- A 5-year average of $763357.1 and a median of $61000.0 in 2023 frame the typical range for Exchange Rate Effect.
- Annual changes were most pronounced in 2024 — Exchange Rate Effect tumbled 10850.0% — and 2025, when it surged 7943.22%.
- Recursion Pharmaceuticals' Exchange Rate Effect stood at -$307000.0 in 2022, then jumped by 140.39% to $124000.0 in 2023, then slumped by 2900.0% to -$3.5 million in 2024, then soared by 160.11% to $2.1 million in 2025, then plunged by 283.61% to -$3.8 million in 2026.
- Business Quant data shows RXRX's Exchange Rate Effect at -$3.8 million in Q1 2026, $2.1 million in Q4 2025, and $1.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Exchange Rate Effect (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 619,347.27 |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 19.32 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | -40.30 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -900,000.00 |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Recursion Pharmaceuticals | 1.57 Bn | 912.05 Mn | -6.02 Mn | -3.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.83 Mn |
| Mar 31, 2026 | -3.83 Mn |
| Dec 31, 2025 | 2.09 Mn |
| Dec 31, 2025 | 2.09 Mn |
| Sep 30, 2025 | 1.87 Mn |
| Sep 30, 2025 | 1.87 Mn |
| Jun 30, 2025 | 9.26 Mn |
| Jun 30, 2025 | 9.26 Mn |
| Mar 31, 2025 | 4.83 Mn |
| Mar 31, 2025 | 4.83 Mn |
| Dec 31, 2024 | -3.47 Mn |
| Dec 31, 2024 | -3.47 Mn |
| Sep 30, 2024 | 403,000.00 |
| Sep 30, 2024 | 403,000.00 |
| Jun 30, 2024 | -118,000.00 |
| Jun 30, 2024 | -118,000.00 |
| Mar 31, 2024 | -219,000.00 |
| Mar 31, 2024 | -219,000.00 |
| Dec 31, 2023 | 124,000.00 |
| Dec 31, 2023 | 124,000.00 |